Last updated on March 2018

Patients are needed to participate in a clinical research study evaluating Placebo, Omecamtiv Mecarbil

Brief description of study

The purpose of this study is to determine if treatment with omecamtiv mecarbil/AMG 423 when added to standard of care is well tolerated and superior to placebo in reducing the risk of cardiovascular death or heart failure events in subjects with chronic HFrEF.

Clinical Study Identifier: NCT02929329

Contact Investigators or Research Sites near you

Start Over

Amgen Call Center

Research Site
Brampton, ON Canada
  Connect »